Dr Rosanne Dunn, Co-Founder and Chief Scientific Officer at HaemaLogiX, authored an article for Drug Discovery World that explored how the discovery of a new class of tumour‑specific antigens is transforming how we treat plasma cell dyscrasias.

"Proteasome inhibitors, immunomodulatory drugs, anti‑CD38 antibodies, and, more recently BCMA‑directed CAR‑T cells and bispecifics, have each extended survival and transformed expectations. But the malignant plasma cell clone adapts, escapes, and ultimately progresses through every line of therapy. The central limitation is not the ingenuity of modalities but the biology of the targets themselves" she said.

Read the full article here.